Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
DNDi Taps Pfizer Compound Library
by Michael McCoy
November 30, 2009
| A version of this story appeared in
Volume 87, Issue 48
Pfizer and the Drugs for Neglected Diseases initiative are joining to advance the development of cures for human African trypanosomiasis, visceral leishmaniasis, and Chagas disease, which afflict people in the developing world. Under the agreement, scientists in institutions affiliated with DNDi will test at least 150,000 compounds in Pfizer’s library of novel chemical entities against the parasites that cause the three diseases. According to DNDi, Pfizer’s compound library has never been explored for treatments for these diseases.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter